Related Experiment Video
Updated: Jul 31, 2026

Candida albicans Biofilm Chip CaBChip for High-throughput Antifungal Drug Screening
Published on: July 18, 2012
Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland
A T Coste1, A Kritikos2, J Li1,2
1Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Abstract:
Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15-77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.
Related Concept Videos
Cryptococcal Meningitis
Candidiasis

